The American Academy of Neurology (AAN) selected joint research by Decode Health and Quest Diagnostics for presentation at its 2023 Annual Meeting.
“We are excited about our ongoing work with Quest Diagnostics,” says Chase Spurlock, PhD, CEO and Co-Founder of Decode Health. “The research we’re presenting at AAN highlights the potential of leveraging AI and machine learning to accelerate discovery and build new technologies that improve patient care.”
The Decode-Quest joint research study compared gene expression differences in the peripheral whole blood of patients with MS versus neuromyelitis optica (NMO), including differences in patients with NMO who are aquaporin-4 (AQP4) antibody positive (AQP4+) versus AQP4 negative NMO (AQP4-). NMO is often confused with multiple sclerosis and requires different therapeutic and monitoring approaches. These findings suggest that RNA-sequencing data derived from peripheral whole blood can identify the characteristic RNAs, immune repertoires, and pathways that distinguish MS from NMO and NMO AQP4+ versus AQP4- individuals. These approaches could lead to novel RNA-based biomarkers to identify patients with demyelinating diseases at their earliest stages and direct therapeutic management.
The presentation occurred during the MS Biomarkers, Immunology and Basic Science session.
The American Academy of Neurology, founded in 1948, works to promote the highest-quality patient-centered neurologic care and enhance its members’ career satisfaction. The organization represents more than 40,000 members.